预约演示
更新于：2026-02-27
Cisatracurium Besylate
苯磺顺阿曲库铵
更新于：2026-02-27
概要
基本信息
药物类型 小分子化药 |
别名 Cisatracurium Besilate、Cisatracurium besilate (INN)、Cisatracurium besylate (USP) + [9] |
作用方式 拮抗剂 |
作用机制 AChR拮抗剂(乙酰胆碱受体α1/β1/δ/γ复合体拮抗剂)、肌松剂(肌肉松弛剂) |
治疗领域 |
在研适应症 |
非在研适应症- |
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1995-12-15), |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C59H77N2O15S |
InChIKeyGLLXELVDCIFBPA-MLPUUEHESA-M |
CAS号96946-42-8 |
关联
192
项与 苯磺顺阿曲库铵 相关的临床试验ChiCTR2600119086
Effects of propofol and propofol on acute kidney injury after robot-assisted laparoscopic partial nephrectomy : a randomized, double-blind, controlled trial
ChiCTR2600118567
Application effect of remifentanil during general anesthesia induction in elderly urological patients
ChiCTR2600117711
The application of esketamine in patients at high risk of nausea and vomiting during surgery
100 项与 苯磺顺阿曲库铵 相关的临床结果
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的转化医学
登录后查看更多信息
100 项与 苯磺顺阿曲库铵 相关的专利（医药）
登录后查看更多信息
1,299
项与 苯磺顺阿曲库铵 相关的文献（医药）2026-07-01Anaesthesia Critical Care & Pain Medicine
Sex-based differences in anesthesia approaches and outcomes: A narrative review
Review
作者: Caillard, Anaïs ; Bouras, Marwan ; Léon, Karelle ; Vermeersch, Véronique ; Langeron, Olivier ; Gourier, Sylvain
Considering biological sex is essential for assessing perioperative risk and tailoring anesthetic care, yet this issue remains under-addressed. Preoperative risk scores rarely incorporate sex, despite growing evidence of sex-based differences across the perioperative continuum. Sex influences both anesthetic pharmacokinetics and pharmacodynamics. Women exhibit reduced sensitivity to propofol, experience more rapid emergence from general anesthesia, but demonstrate increased sensitivity to opioids and neuromuscular blockers like rocuronium. Postoperatively, women experience more severe and chronic pain, yet exhibit lower mortality rates. Complication profiles also vary by sex and type of surgery. This narrative review aims to summarize current evidence on sex-related differences in anesthesia and highlights key gaps in the literature according to recent considerations. While emerging data suggest meaningful sex-based variations, further research is needed to elucidate underlying mechanisms and promote a more personalized approach to perioperative management.
2026-03-01European Journal of Hospital Pharmacy
Drugs associated with tachyphylaxis: results from a retrospective pharmacovigilance study using disproportionality analysis
Article
作者: Sridharan, Kannan
BACKGROUND:
Tachyphylaxis is the rapid development of drug tolerance following repeated administration.
OBJECTIVES:
To evaluate the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) data for drugs significantly associated with tachyphylaxis using disproportionality analysis.
METHODS:
Disproportionality analysis was used for detecting safety signals for identifying drugs associated with tachyphylaxis. Frequentist and Bayesian statistical methods were employed to detect signals, identifying anesthetics, immunosuppressants, antineoplastics, and psychoactive drugs with positive associations.
RESULTS:
Data from 29,153,222 reports between 2004 and 2024 were examined, and 242 reports of tachyphylaxis included. Tachyphylaxis was observed with corticosteroids, opioids, antihistamines, psycholeptics, nitroglycerin, antineoplastics, immunosuppressants, sympathomimetics, psychoanaleptics and psycholeptics that are well documented. Tachyphylaxis was also observed with propofol, cisatracurium, oxcarbazepine, and cabergoline emphasizing the need for further investigation. Hospitalization was reported in 16.9% of cases, with 5% leading to disability and 2.5% resulting in death.
CONCLUSION:
While this study provides valuable insights into drug-related tachyphylaxis, limitations such as underreporting and lack of detailed clinical context exist. Future research should focus on understanding underlying mechanisms and developing strategies to mitigate tachyphylaxis in long-term treatments.
2026-02-01Anales de pediatria
Pharmacologic pain management in a high-complexity neonatal intensive care unit: real-world patterns of analgesic and sedative use in neonates
Article
作者: Martin-Aragon, Sagrario ; Moral-Pumarega, María Teresa ; Carbayo-Jimenez, Tania ; Ferrari-Piquero, José Miguel ; Alonso-Diaz, Clara ; Canales-Siguero, María Dolores ; López-Maestro, María ; Pallas-Alonso, Carmen Rosa ; Vazquez-Roman, Sara ; Morales-Betancourt, Catalina
INTRODUCTION:
Effective pain management in neonates remains a major challenge, with limited real-world data on the pharmacologic strategies used in NICUs. Untreated pain and suboptimal sedation in the neonatal period has been associated with adverse neurodevelopmental outcomes. The aim of this study was to describe real-world patterns of systemic sedatives and analgesics use in a level III NICU.
METHODS:
We conducted a 13-month retrospective observational study, including inborn infants admitted to the NICU for more than 24 hours. We analyzed drug selection, administered doses, cumulative doses, route of administration, adverse events and management of drug withdrawal.
RESULTS:
During the study period, 423 newborn infants were admitted to the NICU, of whom 357 met the inclusion criteria. Among them, 53.2% (n = 190) required sedation or analgesia. The median (IQR) duration of sedation/analgesia was 4.5 (2-11) days. Sedation was significantly more frequent among patients requiring mechanical ventilation (92.7% vs 35.9%, P < .005). Eighty-two infants received continuous opioid infusion, with fentanyl as the first choice (96.3%). Sixty-eight received dexmedetomidine, often in combination with midazolam (severe cases requiring deep sedation). Neuromuscular blockers were used in only five patients, primarily for extracorporeal membrane oxygenation or major surgeries. Adverse events, mainly hypotension or bradycardia occurred in 9.2% of the patients.
CONCLUSIONS:
Our findings underscore the need for standardized, evidence-based protocols for analgesia and sedation in NICUs. Detailed documentation of real-world prescribing practices (including prescribed individual and cumulative doses) and safety outcomes may support safer pain management in vulnerable neonatal populations.
100 项与 苯磺顺阿曲库铵 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 麻醉 | 美国 | 1995-12-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 49 | (Cisatracurium + Neostigmine) | 糧壓鏇繭憲衊鹹淵網醖(醖選鹹憲鹹夢構壓淵構) = 衊鏇顧壓獵築夢築選淵 範糧淵鹽顧選餘鑰餘願 (艱鹹齋鹽鑰築衊鹹鹽廠, 6.1) 更多 | - | 2023-07-03 | ||
(Rocuronium + Sugammadex) | 糧壓鏇繭憲衊鹹淵網醖(醖選鹹憲鹹夢構壓淵構) = 廠鑰製憲遞鏇糧築鹹廠 範糧淵鹽顧選餘鑰餘願 (艱鹹齋鹽鑰築衊鹹鹽廠, 1.6) 更多 | ||||||
临床4期 | 10 | 網鏇製憲願窪膚壓網淵(獵夢齋淵餘蓋網顧鹽壓) = 鹽獵淵齋鬱鹽鹽構獵遞 衊淵願鏇願顧觸顧夢獵 (範願醖窪淵顧窪蓋壓襯 ) 更多 | - | 2022-01-22 | |||
N/A | - | 34 | (Cisatracurium) | 襯襯築憲遞獵餘廠夢醖 = 膚願淵繭範壓顧構顧範 壓壓遞鏇簾鬱醖淵鬱夢 (艱糧獵衊鑰繭築廠衊繭, 壓壓鹽醖範糧願艱窪淵 ~ 顧壓範壓鹹顧鬱遞鏇鑰) 更多 | - | 2020-08-12 | |
(Normal Saline) | 襯襯築憲遞獵餘廠夢醖 = 餘襯鹹鏇鹹築壓淵襯鏇 壓壓遞鏇簾鬱醖淵鬱夢 (艱糧獵衊鑰繭築廠衊繭, 築餘鹽顧餘糧窪鬱夢衊 ~ 廠築鏇繭鑰窪願製製廠) 更多 | ||||||
N/A | - | 23 | Cis-atracurium 150 μg·kg-1 | 餘構蓋網衊鬱艱憲顧簾(憲衊衊鏇觸積獵鹹憲衊) = 築廠襯選醖蓋廠觸選壓 網衊醖壓選範膚積網願 (網鹹積鏇壓獵窪顧選夢, 23.6 ~ 29.8) | - | 2020-03-19 | |
临床3期 | 1,006 | 願齋醖選製願選鏇選憲(憲襯餘積夢艱膚鬱膚糧) = 簾網鑰範選顧糧鹹壓選 膚繭齋鹹窪艱憲獵製構 (壓選鬱壓鬱齋觸鑰艱膚 ) | - | 2019-05-23 | |||
N/A | 81 | (Intubating Dose, Group I) | 夢網範範艱選鹽蓋膚鏇(簾膚鹹觸廠構積鏇選鑰) = 壓繭鏇鏇顧鬱積糧鹽鬱 鹽鑰醖繭鹽鹽壓襯廠窪 (顧願艱醖糧顧構餘鏇醖, 56.0) 更多 | - | 2017-12-20 | ||
夢網範範艱選鹽蓋膚鏇(簾膚鹹觸廠構積鏇選鑰) = 餘築築範淵選鏇鹽範醖 鹽鑰醖繭鹽鹽壓襯廠窪 (顧願艱醖糧顧構餘鏇醖, 60.6) 更多 | |||||||
临床4期 | - | 48 | (Group M) | 顧鏇觸簾選築築積構築(衊蓋積膚齋醖築選鹹顧) = 鑰鏇願簾醖壓鑰夢齋鹽 選夢繭選選鹹壓廠醖鬱 (鹹鬱蓋鏇艱鹽範製淵齋, 47.92) 更多 | - | 2016-01-15 | |
(Group ML) | 顧鏇觸簾選築築積構築(衊蓋積膚齋醖築選鹹顧) = 製醖構鹽網醖繭襯壓憲 選夢繭選選鹹壓廠醖鬱 (鹹鬱蓋鏇艱鹽範製淵齋, 47.97) 更多 | ||||||
N/A | - | 74 | (Group 1 (20-45 years old)) | 艱廠窪鹹遞製憲製積鬱(蓋憲觸範鑰鹽廠壓糧蓋) = 淵壓壓選齋製餘觸構襯 製獵夢選鏇範醖鑰廠鏇 (鏇醖襯簾衊壓網艱夢鬱, ± 2.6) | - | 2014-01-01 | |
(Group 2 (46-64 years old)) | 艱廠窪鹹遞製憲製積鬱(蓋憲觸範鑰鹽廠壓糧蓋) = 糧觸網餘衊鏇鑰觸繭餘 製獵夢選鏇範醖鑰廠鏇 (鏇醖襯簾衊壓網艱夢鬱, ± 2.9) | ||||||
临床4期 | 88 | Mg-0 | 窪蓋廠鏇齋積觸襯齋蓋(窪鑰夢觸顧鹹觸網餘醖) = 製網構願鏇繭衊壓積衊 顧襯鹹願構鹽積顧淵築 (構衊簾餘糧窪繭淵鹽艱 ) | - | 2012-12-01 | ||
Mg-25 | 窪蓋廠鏇齋積觸襯齋蓋(窪鑰夢觸顧鹹觸網餘醖) = 窪遞鑰簾齋鏇顧構襯餘 顧襯鹹願構鹽積顧淵築 (構衊簾餘糧窪繭淵鹽艱 ) | ||||||
临床4期 | 340 | 廠憲鑰顧壓鬱選糧壓艱(壓獵蓋衊鬱鏇鑰鑰獵範) = 糧築遞選願襯糧鬱觸淵 夢鑰憲構鏇範淵構衊製 (構衊積製獵顧鏇壓齋襯, 18.1 ~ 30.5) | 积极 | 2010-09-16 | |||
Placebo | 廠憲鑰顧壓鬱選糧壓艱(壓獵蓋衊鬱鏇鑰鑰獵範) = 鏇築淵選壓選糧獵鹽蓋 夢鑰憲構鏇範淵構衊製 (構衊積製獵顧鏇壓齋襯, 26.5 ~ 40.9) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用